The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLSN | -62.67% | -95.76% | -46.81% | -100% |
| S&P | +12.65% | +91.73% | +13.89% | +1,109% |
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
After a history of failures, these three biotech stocks are running out of ideas and cash to keep their operations going.
A lot of things happened this past week. Let's check it out.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.16M | 11.1% |
| Market Cap | $20.61M | 89.0% |
| Market Cap / Employee | $0.82M | 0.0% |
| Employees | 25 | -24.2% |
| Net Income | -$2.74M | 42.8% |
| EBITDA | -$2.60M | 46.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.73M | -10.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.81M | -7.1% |
| Short Term Debt | $0.38M | -26.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -170.41% | -76.3% |
| Return On Invested Capital | -148.73% | -61.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.97M | 34.1% |
| Operating Free Cash Flow | -$2.95M | 34.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.88 | 3.25 | 33.96 | 7.75 | 503.94% |
| Price to Tangible Book Value | 24.47 | 21.93 | 46.79 | 337.51 | 1916.84% |
| Enterprise Value to EBITDA | -1.31 | -2.27 | -3.40 | -4.53 | 212.97% |
| Return on Equity | -148.1% | -211.2% | -397.5% | -492.0% | 243.58% |
| Total Debt | $1.27M | $1.14M | $1.01M | $1.19M | -14.09% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
